Natural carriers for siRNA delivery

Current Pharmaceutical Design

Volumn 21, Issue 31, 2015, Pages 4529-4540

  Karunaratne, D Nedra ^a   Jafari, Mousa ^b   Ranatunga, R J K Udayana ^a   Siriwardhana, Asitha ^c  

^a UNIVERSITY OF PERADENIYA   (Sri Lanka)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c Sri Lanka Institute of Nanotechnology (SLINTEC)   (Sri Lanka)

Author keywords

Exosomes; Natural polymeric carriers; Peptides; Polysaccharides; SiRNA delivery

Indexed keywords

ADENOVIRUS VECTOR; ALBUMIN; ALGINIC ACID; ATELOCOLLAGEN; CHITOSAN; CYCLODEXTRIN; DEXTRAN; DRUG CARRIER; EXCIPIENT; GELATIN; GLUCAN; HYALURONIC ACID; NANOCARRIER; PENETRATIN; POLYMER; POLYSACCHARIDE; SMALL INTERFERING RNA; TIOPRONIN; VIRUS VECTOR; PEPTIDE; PROTEIN;

ADENOVIRIDAE; BIOCOMPATIBILITY; CONJUGATION; CROSS LINKING; DEACETYLATION; DERIVATIZATION; DNA MODIFICATION; EXOSOME; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC MANIPULATION; GENETIC TRANSFECTION; HERPES SIMPLEX VIRUS; HYDROPHILICITY; IMMUNOGENICITY; LENTIVIRINAE; MOLECULAR WEIGHT; NONVIRAL GENE DELIVERY SYSTEM; PARTICLE SIZE; PH; POXVIRIDAE; PRIORITY JOURNAL; RETROVIRIDAE; REVIEW; STATIC ELECTRICITY; VIRAL GENE DELIVERY SYSTEM; ZETA POTENTIAL; ANIMAL; CHEMISTRY; GENE THERAPY; GENE TRANSFER; GENE VECTOR; HUMAN; PROCEDURES;

ANIMALS; CHITOSAN; EXOSOMES; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HUMANS; PEPTIDES; POLYSACCHARIDES; PROTEINS; RNA, SMALL INTERFERING;

EID: 84946722211     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282131151013185528     Document Type: Review

References (154)

1. [1] Kozielski KL, Tzeng SY, Green JJ. Bioengineered nanoparticlesfor siRNA delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2013; 5: 449-68.
2. [2] Thomas CE, Ehrhardt A, Kay MA. Progress and problems with theuse of viral vectors for gene therapy. Nat Rev Genet 2003; 4: 346-58.
3. [3] Hong CA, Nam YS. Functional nanostructures for effective deliv-ery of small interfering RNA therapeutics. Theranostics 2014; 4: 1211-32.
4. [4] Khurana B, Goyal AK, Budhiraja A, Arora D, Vyas SP. siRNAdelivery using nanocarriers an efficient tool for gene silencing. Curr Gene Ther 2010; 10: 139-55.
5. [5] Dang JM, Leong KW. Natural polymers for gene delivery andtissue engineering. Adv Drug Deliv Rev 2006; 58: 487-99.
6. [6] Nguyen J, Xie X, Neu M, et al. Effects of cell-penetrating peptidesand pegylation on transfection efficiency of polyethylenimine in mouse lungs. J Gene Med 2008; 10: 1236-46.
7. [7] Zufferey R, Nagy D, Mandel RJ, Naldini L, Trono D. Multiplyattenuated lentiviral vector achieves efficient gene delivery in vivo. Nat Biotechnol 1997; 15: 871-5.
8. [8] Zufferey R, Dull T, Mandel RJ, et al. Self-inactivating lentivirusvector for safe and efficient in vivo gene delivery. J Virol 1998; 72: 9873-80.
9. [9] Misra A., Ed. Challenges in Delivery of Therapeutic Genomics andProteomics. Elseiver: London 2011.
10. [10] Ponder KP. Vectors of Gene Therapy. In: Kresina TF, ed.^eds., Anintroduction to molecular medicine and gene therapy. Wiley-Liss, Inc.: New York USA 2001; pp. 77-112.
11. [11] Palfi S, Gurruchaga JM, Ralph GS, et al. Long-term safety andtolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial. Lancet 383: 1138-46.
12. [12] Wagner E. Polymers for siRNA delivery: inspired by viruses to betargeted, dynamic, and precise. Acc Chem Res 2012; 45: 1005-13.
13. [13] Liu Z, Winters M, Holodniy M, Dai H. siRNA delivery into humanT cells and primary cells with carbon-nanotube transporters. Angew Chem Int Ed Engl 2007; 46: 2023-7.
14. [14] Wickham TJ, Roelvink PW, Brough DE, Kovesdi I. Adenovirustargeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat Biotechnol 1996; 14: 1570-3.
15. [15] Alemany R, Curiel DT. CAR-binding ablation does not changebiodistribution and toxicity of adenoviral vectors. Gene Ther 2001; 8: 1347-53.
16. [16] Wu GY, Wu CH. Receptor-mediated gene delivery and expressionin vivo. J Biol Chem 1988; 263: 14621-4.
17. [17] Fernandes JC, Qiu X, Winnik FM, et al. Low molecular weightchitosan conjugated with folate for siRNA delivery in vitro: optimization studies. Int J Nanomed 2012; 7: 5833-45.
18. [18] Khan W, Hosseinkhani H, Ickowicz D, Hong PD, Yu DS, DombAJ. Polysaccharide gene transfection agents. Acta Biomater 2012; 8: 4224-32.
19. [19] Kumar MN, Muzzarelli RA, Muzzarelli C, Sashiwa H, Domb AJ.Chitosan chemistry and pharmaceutical perspectives. Chem Rev 2004; 104: 6017-84.
20. [20] Mao H-Q, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparti-cles as gene carriers: synthesis, characterization and transfection efficiency. J Control Release 2001; 70: 399-421.
21. [21] Chandy T, Sharma CP. Chitosan as a biomaterial. Biomater ArtifCells Artif Organs 1990; 18: 1-24.
22. [22] Illum L. Chitosan and its use as a pharmaceutical excipient. PharmRes 1998; 15: 1326-31.
23. [23] Kean T, Thanou M. Biodegradation, biodistribution and toxicity ofchitosan. Adv Drug Deliv Rev 2010; 62: 3-11.
24. [24] Hung TH, Chang YM, Sung HY, Chang CT. Purification and char-acterization of hydrolase with chitinase and chitosanase activity from commercial stem bromelain. J Agric Food Chem 2002; 50: 4666-73.
25. [25] Kuroiwa T, Ichikawa S, Sato S, Mukataka S. Improvement of theyield of physiologically active oligosaccharides in continuous hydrolysis of chitosan using immobilized chitosanases. Biotechnol Bioeng 2003; 84: 121-7.
26. [26] Muzzarelli RAA, Tomasetti M, Ilari P. Deploymerization of chito-san with the aid of papain. Enzyme Microbial Technol 1994; 16: 110-4.
27. [27] Li J, Du Y, Liang H. Influence of molecular parameters on thedegradation of chitosan by a commercial enzyme. Polymer Degradation and Stability 2007; 92: 515-24.
28. [28] Nordtveit RJ, Vårum KM, Smidsrød O. Degradation of fully water-soluble, partially N-acetylated chitosans with lysozyme. Carbohydr Polym 1994; 23: 253-60.
29. [29] Koping-Hoggard M, Tubulekas I, Guan H, et al. Chitosan as anonviral gene delivery system. Structure-property relationships and characteristics compared with polyethylenimine in vitro and after lung administration in vivo. Gene Ther 2001; 8: 1108-21.
30. [30] Madihally SV, Matthew HW. Porous chitosan scaffolds for tissueengineering. Biomaterials 1999; 20: 1133-42.
31. [31] Mumper RL, Wang JJ, Claspell JM, Rolland AP. Novel polymericcondensing carriers for gene delivery. Proc Int Sym Control Release Bioact 1995; 22: 178-9.
32. [32] Erbacher P, Zou S, Bettinger T, Steffan A-M, Remy J-S. Chitosan-based vector/DNA complexes for gene delivery: biophysical characteristics and transfection ability. Pharm Res 1998; 15: 1332-9.
33. [33] MacLaughlin FC, Mumper RJ, Wang J, et al. Chitosan and de-polymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release 1998; 56: 259-72.
34. [34] Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery withchitosan--DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5: 387-91.
35. [35] Ozbas-Turan S, Aral C, Kabasakal L, Keyer-Uysal M, Akbuga J. Co-encapsulation of two plasmids in chitosan microspheres as a non-viral gene delivery vehicle. J Pharm Pharm Sci 2003; 6: 27-32.
36. [36] Tong H, Qin S, Fernandes JC, Li L, Dai K, Zhang X. Progress andprospects of chitosan and its derivatives as non-viral gene vectors in gene therapy. Curr Gene Ther 2009; 9: 495-502.
37. [37] Mao S, Sun W, Kissel T. Chitosan-based formulations for deliveryof DNA and siRNA. Adv Drug Deliv Rev 2010; 62: 12-27.
38. [38] Xu S, Dong M, Liu X, Howard KA, Kjems J, Besenbacher F. Di-rect force measurements between siRNA and chitosan molecules using force spectroscopy. Biophysical J 2007; 93: 952-9.
39. [39] Liu X, Howard KA, Dong M, et al. The influence of polymericproperties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials 2007; 28: 1280-8.
40. [40] Corsi K, Chellat F, Yahia LH, Fernandes JC. Mesenchymal stemcells, MG63 and HEK293 transfection using chitosan-DNA nanoparticles. Biomaterials 2003; 24: 1255-64.
41. [41] Sato T, Ishii T, Okahata Y. In vitro gene delivery mediated bychitosan. Effect of pH, serum, and molecular mass of chitosan on the transfection efficiency. Biomaterials 2001; 22: 2075-80.
42. [42] Rudzinski WE, Aminabhavi TM. Chitosan as a carrier for targeteddelivery of small interfering RNA. Int J Pharm 2010; 399: 1-11.
43. [43] Huang M, Fong C-W, Khor E, Lim L-Y. Transfection efficiency ofchitosan vectors: Effect of polymer molecular weight and degree of deacetylation. J Control Release 2005; 106: 391-406.
44. [44] Nafee N, Taetz S, Schneider M, Schaefer UF, Lehr CM. Chitosan-coated PLGA nanoparticles for DNA/RNA delivery: effect of the formulation parameters on complexation and transfection of antisense oligonucleotides. Nanomedicine 2007; 3: 173-83.
45. [45] Alameh M, DeJesus D, Jean M, et al. Low molecular weight chito-san nanoparticulate system at low N:P ratio for nontoxic polynucleotide delivery. Int J Nanomed 2012; 7: 1399-414.
46. [46] Gao S, Hein S, Dagnaes-Hansen F, et al. Megalin-mediated spe-cific uptake of chitosan/siRNA nanoparticles in mouse kidney proximal tubule epithelial cells enables AQP1 gene silencing. Theranostics 2014; 4: 1039-51.
47. [47] Weecharangsan W, Opanasopit P, Ngawhirunpat T, et al. Evalua-tion of chitosan salts as non-viral gene vectors in CHO-K1 cells. Int J Pharm 2008; 348: 161-8.
48. [48] Tomihata K, Ikada Y. In vitro and in vivo degradation of films ofchitin and its deacetylated derivatives. Biomaterials 1997; 18: 567-75.
49. [49] Ballarin-Gonzalez B, Dagnaes-Hansen F, Fenton RA, et al. Protec-tion and systemic translocation of siRNA following oral administration of Chitosan/siRNA nanoparticles. Mol Ther Nucleic Acids 2013; 2: e76.
50. [50] Rojanarata T, Opanasopit P, Techaarpornkul S, Ngawhirunpat T, Ruktanonchai U. Chitosan-thiamine pyrophosphate as a novel carrier for siRNA delivery. Pharm Res 2008; 25: 2807-14.
51. [51] Malhotra M, Kulamarva A, Sebak S, et al. Ultrafine chitosannanoparticles as an efficient nucleic acid delivery system targeting neuronal cells. Drug Dev Ind Pharm 2009; 35: 719-26.
52. [52] Duan Y, Guan X, Ge J, et al. Cationic nano-copolymers mediatedIKK targeting siRNA inhibit the proliferation of human Tenon’s capsule fibroblasts in vitro. Mol Vision 2008; 14: 2616-28.
53. [53] Gary DJ, Puri N, Won YY. Polymer-based siRNA delivery: per-spectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J Control Release 2007; 121: 64-73.
54. [54] Lee DW, Yun K-S, Ban H-S, Choe W, Lee SK, Lee KY. Prepara-tion and characterization of chitosan/polyguluronate nanoparticles for siRNA delivery. J Control Release 2009; 139: 146-52.
55. [55] Liao ZX, Ho YC, Chen HL, Peng SF, Hsiao CW, Sung HW. En-hancement of efficiencies of the cellular uptake and gene silencing of chitosan/siRNA complexes via the inclusion of a negatively charged poly(gamma-glutamic acid). Biomaterials 2010; 31: 8780-8788.
56. [56] Ghosn B, Singh A, Li M, et al. Efficient gene silencing in lungsand liver using imidazole-modified chitosan as a nanocarrier for small interfering RNA. Oligonucleotides 2010; 20: 163-72.
57. [57] Howard KA, Rahbek UL, Liu X, et al. RNA interference in vitroand in vivo using a novel chitosan/siRNA nanoparticle system. Mol Ther 2006; 14: 476-84.
58. [58] Katas H, Alpar HO. Development and characterisation of chitosannanoparticles for siRNA delivery. J Control Release 2006; 115: 216-25.
59. [59] Behlke MA. Progress towards in vivo use of siRNAs. Mol Ther2006; 13: 644-70.
60. [60] Guo P, Coban O, Snead NM, et al. Engineering RNA for targetedsiRNA delivery and medical application. Adv Drug Deliv Rev 2010; 62: 650-66.
61. [61] Douglas KL, Piccirillo CA, Tabrizian M. Cell line-dependent inter-nalization pathways and intracellular trafficking determine transfection efficiency of nanoparticle vectors. Eur J Pharm Biopharm 2008; 68: 676-87.
62. [62] Shi Q, Tiera MJ, Zhang X, Dai K, Benderdour M, Fernandes JC. Eds. Chitosan-DNA/siRNA Nanoparticles for Gene Therapy. In-Tech: Rijeka, Croatia 2011.
63. [63] Ravina M, Cubillo E, Olmeda D, et al. Hyaluronic acid/chitosan-g-poly(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery. Pharm Res 2010; 27: 2544-55.
64. [64] Wang Y, Liu P, Du J, Sun Y, Li F, Duan Y. Targeted siRNA deliv-ery by anti-HER2 antibody-modified nanoparticles of mPEG-chitosan diblock copolymer. J Biomater Sci Polym Ed 2013; 24: 1219-32.
65. [65] Ragelle H, Riva R, Vandermeulen G, et al. Chitosan nanoparticlesfor siRNA delivery: optimizing formulation to increase stability and efficiency. J Control Release 2014; 176: 54-63.
66. [66] Noh SM, Park MO, Shim G, et al. Pegylated poly-l-arginine de-rivatives of chitosan for effective delivery of siRNA. J Control Release 2010; 145: 159-64.
67. [67] Plianwong S, Opanasopit P, Ngawhirunpat T, Rojanarata T. Chito-san combined with poly-L-arginine as efficient, safe, and seruminsensitive vehicle with RNase protection ability for siRNA delivery. BioMed Res Int 2013; 2013: 9.
68. [68] Ki MH, Kim JE, Lee YN, et al. Chitosan-based hybrid nanocom-plex for siRNA delivery and its application for cancer therapy. Pharm Res 2014; 31: 3323-34.
69. [69] Gwak SJ, Jung JK, An SS, et al. Chitosan/TPP-hyaluronic acidnanoparticles: a new vehicle for gene delivery to the spinal cord. J Biomater Sci Polym Ed 2011.
70. [70] Al-Qadi S, Alatorre-Meda M, Zaghloul EM, Taboada P, Remunán-López C. Chitosan-hyaluronic acid nanoparticles for gene silencing: The role of hyaluronic acid on the nanoparticles’ formation and activity. Colloids Surfaces B: Biointerfaces 2013; 103: 615-23.
71. [71] Ma Z, Yang C, Song W, Wang Q, Kjems J, Gao S. Chitosan Hy-drogel as siRNA vector for prolonged gene silencing. J Nanobiotechnol 2014; 12: 23.
72. [72] Han HD, Mora EM, Roh JW, et al. Chitosan hydrogel for localizedgene silencing. Cancer Biol Ther 2011; 11: 839-45.
73. [73] Saranya N, Moorthi A, Saravanan S, Devi MP, Selvamurugan N. Chitosan and its derivatives for gene delivery. Int J Biol Macromol 2011; 48: 234-8.
74. [74] Han HD, Mangala LS, Lee JW, et al. Targeted gene silencing usingRGD-labeled chitosan nanoparticles. Clin Cancer Res 2010; 16: 3910-22.
75. [75] Soto ER, Caras AC, Kut LC, Castle MK, Ostroff GR. Glucan parti-cles for macrophage targeted delivery of nanoparticles. J Drug Deliv. 2012; 2012: 13.
76. [76] Aouadi M, Tencerova M, Vangala P, et al. Gene silencing in adi-pose tissue macrophages regulates whole-body metabolism in obese mice. Proc Natl Acad Sci USA 2013; 110: 8278-83.
77. [77] Soto E, Ostroff G. Glucan particles as an efficient siRNA deliveryvehicle. Nanotechnology 2008; 2: 332-5.
78. [78] Tesz GJ, Aouadi M, Prot M, et al. Glucan particles for selectivedelivery of siRNA to phagocytic cells in mice. Biochem J 2011; 436: 351-62.
79. [79] Ishii T, Okahata Y, Sato T. Mechanism of cell transfection withplasmid/chitosan complexes. Biochim Biophys Acta 2001; 1514: 51-64.
80. [80] Samal SK, Dash M, Van Vlierberghe S, et al. Cationic polymersand their therapeutic potential. Chem Soc Rev 2012; 41: 7147-94.
81. [81] Cohen JL, Schubert S, Wich PR, et al. Acid-degradable cationicdextran particles for the delivery of siRNA therapeutics. Bioconjug Chem 2011; 22: 1056-65.
82. [82] Abedini F, Hosseinkhani H, Ismail M, et al. Cationized dextrannanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. Int J Nanomed 2012; 7: 4159-68.
83. [83] Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeu-tics: barriers and carriers. AAPS J 2010; 12: 492-503.
84. [84] Cryan SA, Holohan A, Donohue R, Darcy R, O'Driscoll CM. Celltransfection with polycationic cyclodextrin vectors. Eur J Pharm Sci 2004; 21: 625-33.
85. [85] McCarthy J, O'Neill MJ, Bourre L, et al. Gene silencing of TNF-alpha in a murine model of acute colitis using a modified cyclodextrin delivery system. J Control Release 2013; 168: 28-34.
86. [86] Davis ME. The First Targeted Delivery of siRNA in Humans via aSelf-Assembling, Cyclodextrin Polymer-Based Nanoparticle: From Concept to Clinic. Mol Pharma 2009; 6: 659-68.
87. [87] Heidel JD, Yu Z, Liu JY-C, et al. Administration in non-humanprimates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA. Proc Natl Acad Sci 2007; 104: 5715-21.
88. [88] Li N, Luo HC, Yang C, et al. Cationic star-shaped polymer as ansiRNA carrier for reducing MMP-9 expression in skin fibroblast cells and promoting wound healing in diabetic rats. Int J Nanomed 2014; 9: 3377-87.
89. [89] Jana S, Gandhi A, Kk S, Sk B. Natural polymers and their applica-tion in drug delivery and biomedical field. J PharmaSciTech 2011; 1: 16-27.
90. [90] Zhao D, Zhuo RX, Cheng SX. Alginate modified nanostructuredcalcium carbonate with enhanced delivery efficiency for gene and drug delivery. Mol Biosyst 2012; 8: 753-9.
91. [91] Li X, Chen Y, Wang M, Ma Y, Xia W, Gu H. A mesoporous silicananoparticle--PEI--fusogenic peptide system for siRNA delivery in cancer therapy. Biomaterials 2013; 34: 1391-401.
92. [92] Patnaik S, Arif M, Pathak A, Singh N, Gupta KC. PEI-alginatenanocomposites: efficient non-viral vectors for nucleic acids. Int J Pharm 2010; 385: 194-202.
93. [93] Laroui H, Geem D, Xiao B, et al. Targeting intestinal inflammationwith CD98 siRNA/PEI-loaded nanoparticles. Mol Ther 2014; 22: 69-80.
94. [94] Gazori T, Haririan I, Fouladdel S, Namazi A, Nomani A, Azizi E. Inhibition of EGFR expression with chitosan/alginate nanoparticles encapsulating antisense oligonucleotides in T47D cell line using RT-PCR and immunocytochemistry. Carbohydr Polym 2010; 80: 1042-7.
95. [95] Wu SY, Chang HI, Burgess M, McMillan NA. Vaginal delivery ofsiRNA using a novel PEGylated lipoplex-entrapped alginate scaffold system. J Control Release 2011; 155: 418-26.
96. [96] Kim YH, Lee JW. Targeting of focal adhesion kinase by smallinterfering RNAs reduces chondrocyte redifferentiation capacity in alginate beads culture with type II collagen. J Cell Physiol 2009; 218: 623-30.
97. [97] Toole BP. Hyaluronan: from extracellular glue to pericellular cue. Nat Rev Cancer 2004; 4: 528-39.
98. [98] Yang X, lyer AK, Singh A, et al. MDR1 siRNA loaded hyaluronicacid-based CD44 targeted nanoparticle systems circumvent paclitaxel resistance in ovarian cancer. Sci Rep 2015; 5.
99. [99] Kim EJ, Shim G, Kim K, Kwon IC, Oh YK, Shim CK. Hyaluronicacid complexed to biodegradable poly L-arginine for targeted delivery of siRNAs. J Gene Med 2009; 11: 791-803.
100. [100] Ghosh SC, Neslihan Alpay S, Klostergaard J. CD44: a validatedtarget for improved delivery of cancer therapeutics. Expert Opin Ther Targets 2012; 16: 635-50.
101. [101] Han SE, Kang H, Shim GY, et al. Cationic derivatives of biocom-patible hyaluronic acids for delivery of siRNA and antisense oligonucleotides. J Drug Target 2009; 17: 123-32.
102. [102] Jiang G, Park K, Kim J, et al. Hyaluronic acid-polyethyleneimineconjugate for target specific intracellular delivery of siRNA. Biopolymers 2008; 89: 635-42.
103. [103] Ganesh S, Iyer AK, Morrissey DV, Amiji MM. Hyaluronic acidbased self-assembling nanosystems for CD44 target mediated siRNA delivery to solid tumors. Biomaterials 2013; 34: 3489-502.
104. [104] Choi KY, Chung H, Min KH, et al. Self-assembled hyaluronic acidnanoparticles for active tumor targeting. Biomaterials 2010; 31: 106-14.
105. [105] Lee H, Mok H, Lee S, Oh YK, Park TG. Target-specific intracellu-lar delivery of siRNA using degradable hyaluronic acid nanogels. J Control Release 2007; 119: 245-52.
106. [106] Jafari M, Xu W, Naahidi S, Chen B, Chen P. A new amphipathic,amino-acid-pairing (AAP) peptide as siRNA delivery carrier: physicochemical characterization and in vitro uptake. J Phys Chem B 2012; 116: 13183-91.
107. [107] Akhtar S, Benter IF. Nonviral delivery of synthetic siRNAs in vivo.J Clin Investig 2007; 117: 3623-32.
108. [108] Eguchi A, Dowdy SF. siRNA delivery using peptide transductiondomains. Trends Pharmacol Sci 2009; 30: 341-5.
109. [109] Jafari M, Chen P. Peptide mediated siRNA delivery. Curr Top MedChem 2009; 9: 1088-97.
110. [110] Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basicdomain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
111. [111] Kanazawa T, Akiyama F, Kakizaki S, Takashima Y, Seta Y. Deliv-ery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles. Biomaterials 2013; 34: 9220-6.
112. [112] Moschos SA, Jones SW, Perry MM, et al. Lung delivery studiesusing siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007; 18: 1450-9.
113. [113] Deshayes S, Plenat T, Aldrian-Herrada G, et al. Primary amphipa-thic cell-penetrating peptides: structural requirements and interactions with model membranes. Biochemistry 2004; 43: 7698-706.
114. [114] Crombez L, Aldrian-Herrada G, Konate K, et al. A new potentsecondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2009; 17: 95-103.
115. [115] Jafari M, Karunaratne DN, Sweeting CM, Chen P. Modification ofa designed amphipathic cell-penetrating peptide and its effect on solubility, secondary structure, and uptake efficiency. Biochemistry 2013; 52: 3428-35.
116. [116] Jafari M, Xu W, Pan R, Sweeting CM, Karunaratne DN, Chen P. Serum Stability and Physicochemical Characterization of a Novel Amphipathic Peptide C6M1 for SiRNA Delivery. PLoS One 2014; 9: e97797.
117. [117] Xu W, Jafari M, Yuan F, et al. In vitro and in vivo therapeuticsiRNA delivery induced by a tryptophan-rich endosomolytic peptide. J Mater Chem B 2014; 2: 6010-19.
118. [118] Sadatmousavi P, Soltani M, Nazarian R, Jafari M, Chen P. Self-assembling peptides: potential role in tumor targeting. Current pharmaceutical biotechnology. Curr Pharm Biotechnol 2011; 12: 1089-100.
119. [119] Levine RM, Scott CM, Kokkoli E. Peptide functionalized nanopar-ticles for nonviral gene delivery. Soft Matter 2013; 9: 985-1004.
120. [120] Kaneshiro TL, Lu ZR. Targeted intracellular codelivery of che-motherapeutics and nucleic acid with a well-defined dendrimer-based nanoglobular carrier. Biomaterials 2009; 30: 5660-6.
121. [121] Hsu T, Mitragotri S. Delivery of siRNA and other macromoleculesinto skin and cells using a peptide enhancer. Proc Natl Acad Sci 2011; 108: 15816-21.
122. [122] Magzoub M, Sandgren S, Lundberg P, et al. N-terminal peptidesfrom unprocessed prion proteins enter cells by macropinocytosis. Biochem Biophys Res Commun 2006; 348: 379-85.
123. [123] Pooga M, Hallbrink M, Zorko M, Langel U. Cell penetration bytransportan. FASEB J 1998; 12: 67-77.
124. [124] Gros E, Deshayes S, Morris MC, et al. A non-covalent peptide-based strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 2006; 1758: 384-93.
125. [125] Law M, Jafari M, Chen P. Physicochemical characterization ofsiRNA-peptide complexes. Biotechnol Prog 2008; 24: 957-63.
126. [126] Oehlke J, Scheller A, Wiesner B, et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1998; 1414: 127-39.
127. [127] Zhang H, Gerson T, Varney ML, Singh RK, Vinogradov SV. Mul-tifunctional peptide-PEG intercalating conjugates: programmatic of gene delivery to the blood-brain barrier. Pharm Res 2010; 27: 2528-43.
128. [128] Binétruy-Tournaire R, Demangel C, Malavaud B, et al. Identifica-tion of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000; 19: 1525-33.
129. [129] Rajotte D, Ruoslahti E. Membrane dipeptidase is the receptor for a lung-targeting peptide identified by in vivo phage display. J BiolChem 1999; 274: 11593-8.
130. [130] Ruoslahti E. Targeting tumor vasculature with homing peptides from phage display. Semin Cancer Biol 2000; 10: 435-42.
131. [131] Wu P, Leinonen J, Koivunen E, Lankinen H, Stenman U-H. Identi-fication of novel prostate-specific antigen-binding peptides modulating its enzyme activity. Eur J Biochem 2000; 267: 6212-20.
132. [132] Midoux P, Pichon C, Yaouanc J-J, Jaffrès P-A. Chemical vectorsfor gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers. Br J Pharmacol 2009; 157: 166-78.
133. [133] Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raftmacropinocytosis. Nat Med 2004; 10: 310-5.
134. [134] Li X, Chen Y, Wang M, Ma Y, Xia W, Gu H. A mesoporous silica nanoparticle -PEI -Fusogenic peptide system for siRNA deliveryin cancer therapy. Biomaterials 2013; 34: 1391-401.
135. [135] Nam HY, Kim J, Kim S, Yockman JW, Kim SW, Bull DA. Cell penetrating peptide conjugated bioreducible polymer for siRNA de-livery. Biomaterials 2011; 32: 5213-22.
136. [136] Tagalakis AD, He L, Saraiva L, Gustafsson KT, Hart SL. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials 2011; 32: 6302-15.
137. [137] Tagalakis AD, Lee do HD, Bienemann AS, et al. Multifunctional, self-assembling anionic peptide-lipid nanocomplexes for targetedsiRNA delivery. Biomaterials 2014; 35: 8406-15.
138. [138] Zeng H, Little HC, Tiambeng TN, Williams GA, Guan Z. Multifunctional dendronized peptide polymer platform for safe and ef-fective siRNA delivery. J Am Chem Soc 2013; 135: 4962-5.
139. [139] Li H, Tsui T. Six-cell penetrating peptide-based fusion proteins forsiRNA delivery. Drug Deliv. 2014.
140. [140] Minakuchi Y, Takeshita F, Kosaka N, et al. Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. Nucleic Acids Res 2004; 32: e109.
141. [141] Takeshita F, Minakuchi Y, Nagahara S, et al. Efficient delivery ofsmall interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci USA 2005; 102: 12177-82.
142. [142] Takei Y, Kadomatsu K, Yuzawa Y, Matsuo S, Muramatsu T. Asmall interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004; 64: 3365-70.
143. [143] Youngren SR, Tekade RK, Gustilo B, Hoffmann PR, Chougule MB. STAT6 siRNA matrix-loaded gelatin nanocarriers: formulation, characterization, and ex vivo proof of concept using adenocarcinoma cells. BioMed Res Int 2013; 2013: 13.
144. [144] Xu J, Ganesh S, Amiji M. Non-condensing polymeric nanoparticlesfor targeted gene and siRNA delivery. Int J Pharm 2012; 427: 21-34.
145. [145] Karimi M, Avci P, Mobasseri R, Hamblin MR, Naderi-Manesh H. The novel albumin-chitosan core-shell nanoparticles for gene delivery: preparation, optimization and cell uptake investigation. J Nanopart Res 2013; 15: 1651.
146. [146] El-Andaloussi S, Lee Y, Lakhal-Littleton S, et al. Exosome-mediated delivery of siRNA in vitro and in vivo. Nat Protoc 2012; 7: 2112-26.
147. [147] Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. Exosomes are natural carriers of exogenous siRNA to human cells in vitro. Cell Commun Signal 2013; 11: 88.
148. [148] Banizs AB, Huang T, Dryden K, et al. In vitro evaluation of endo-thelial exosomes as carriers for small interfering ribonucleic acid delivery. Int J Nanomed 2014; 9: 4223-30.
149. [149] Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of tar-geted exosomes. Nat Biotech 2011; 29: 341-5.
150. [150] Lakhal S, Wood MJA. Exosome nanotechnology: An emerging paradigm shift in drug delivery. BioEssays 2011; 33: 737-41.
151. [151] Ramachandran S, Palanisamy V. Horizontal transfer of RNAs:exosomes as mediators of intercellular communication. Wiley Interdiscip Rev RNA 2012; 3: 286-93.
152. [152] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novelmechanism of genetic exchange between cells. Nat Cell Biol 2007; 9: 654-9.
153. [153] MacDiarmid JA, Brahmbhatt H. Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy. Curr Opin Biotechnol2011; 22: 909-16.
154. [154] MacDiarmid JA, Amaro-Mugridge NB, Madrid-Weiss J, et al. Sequential treatment of drug-resistant tumors with targetedminicells containing siRNA or a cytotoxic drug. Nat Biotech 2009; 27: 643-51.